Anavex Life Sciences is dedicated to the development of novel drug candidates to treat central nervous system (CNS) diseases, pain and various types of cancer. The company’s lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, are currently being evaluated in a phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 has successfully completed a phase 1 study with a clean data profile. Preclinical studies demonstrate its potential to halt and/or reverse the course of Alzheimer’s disease. The drug combination, ANAVEX PLUS, produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. For more information, visit the company’s website at www.anavex.com